HomeInsightsStock Comparison

Ind Swift Laboratories Ltd vs Kobo Biotech Ltd Stock Comparison

Ind Swift Laboratories Ltd vs Kobo Biotech Ltd Stock Comparison

Last Updated on: Jul 08, 2025

Key Highlights

  • The Latest Trading Price of Ind-Swift Laboratories Ltd is ₹ 122.85 as of 08 Jul 09:09.
  • The P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 1.4 on March 2024 . This represents a CAGR of -54.96% over 2 yearsThe P/E Ratio of Kobo Biotech Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Ind-Swift Laboratories Ltd changed from ₹ 128.22 crore on March 2020 to ₹ 580.82 crore on March 2024 . This represents a CAGR of 35.27% over 5 yearsThe Market Cap of Kobo Biotech Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of Ind-Swift Laboratories Ltd for the Dec '24 is ₹ 22.48 crore as compare to the Sep '24 revenue of ₹ 24.96 crore. This represent the decline of -9.94% The revenue of Kobo Biotech Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Ind-Swift Laboratories Ltd for the Dec '24 is ₹ -0.72 crore as compare to the Sep '24 ebitda of ₹ 1.21 crore. This represent the decline of -159% The ebitda of Kobo Biotech Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Ind-Swift Laboratories Ltd changed from ₹ 17.4 crore to ₹ -0.01 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Kobo Biotech Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Ind-Swift Laboratories Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Kobo Biotech Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Ind-Swift Laboratories Ltd

  • Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, India.
  • The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
  • Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
  • Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
  • Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

About Kobo Biotech Ltd

  • Kobo Biotech Ltd.(Formerly known Avon Lifesciences Ltd) was established as a Public Limited Company on August 3, 1992.
  • Effective 19th October, 2020, the Company's name was changed to Kobo Biotech Limited from erstwhile Avon Lifesciences Limited.
  • The Company is a customer-centric manufacturer of active pharmaceutical ingredients (API).Promoted by P R Agarwal, Rajesh Agarwal and G S Sidhu, the Company manufacture diketene and its derivatives Monomethyl Acetoncetamide(MMA) and Methyl Acetoacetate(MAA). The company's 1200 tpa Diketene manufacturing faciltiy located at Sadashivpet in Andhrapradesh and the products of it were used in pigments, pharmaceuticals and pesticides. The company has a tripartite technical knowhow agreement with Shanghai Machinery & Equipment Import and Export Corporation (SMEC), representative of Shanghai Peng Pu Chemical Works (SPCW) and Xytel Technologies Partnership (XTP), US.

Ind-Swift Laboratories Ltd News Hub

News

Ind-Swift Laboratories schedules board meeting

Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 30 ...

Read more

24 May 2025 18:25

News

Ind-Swift Laboratories adjourns board meeting

Ind-Swift Laboratories has adjourned the meeting of the Board of Directors which was sched...

Read more

14 Feb 2025 11:01

News

Ind-Swift Laboratories announces cessation of director

Ind-Swift Laboratories announced the cessation of Dr. Ashwani Kumar Vig as Independent Dir...

Read more

13 Feb 2025 19:26

News

Ind-Swift Laboratories adjourns board meeting

Ind-Swift Laboratories has adjourned the meeting of the Board of Directors which was sched...

Read more

13 Feb 2025 11:33

News

Ind-Swift Laboratories to announce Quarterly Result

Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 12 ...

Read more

07 Feb 2025 16:48

News

Ind-Swift Laboratories to hold EGM

Ind-Swift Laboratories announced that an Extra Ordinary General Meeting (EGM) of the Compa...

Read more

21 Jan 2025 14:05

Kobo Biotech Ltd News Hub

News

Kobo Biotech to discuss results

Kobo Biotech will hold a meeting of the Board of Directors of the Company on 14 August 202...

Read more

13 Aug 2024 10:21

News

Kobo Biotech to convene board meeting

Kobo Biotech will hold a meeting of the Board of Directors of the Company on 30 May 2024 P...

Read more

28 May 2024 15:31

News

Kobo Biotech to conduct board meeting

Kobo Biotech will hold a meeting of the Board of Directors of the Company on 14 February 2...

Read more

09 Feb 2024 14:57

News

Kobo Biotech to hold board meeting

Kobo Biotech will hold a meeting of the Board of Directors of the Company on 10 November 2...

Read more

03 Nov 2023 17:17

News

Kobo Biotech to hold AGM

Kobo Biotech announced that the 30th Annual General Meeting (AGM) of the company will be h...

Read more

09 Sep 2023 18:44

News

Kobo Biotech to declare Quarterly Result

Kobo Biotech will hold a meeting of the Board of Directors of the Company on 11 August 202...

Read more

07 Aug 2023 13:02

SWOT Analysis Of Ind-Swift Laboratories Ltd

Strength

5

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Kobo Biotech Ltd

Strength

1

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Ind-Swift Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Kobo Biotech Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Ind-Swift Laboratories Ltd and Kobo Biotech Ltd

Which company has a larger market capitalization, Ind-Swift Laboratories Ltd or Kobo Biotech Ltd?

Market cap of Ind-Swift Laboratories Ltd is 726 Cr while Market cap of Kobo Biotech Ltd is 5 Cr

What are the key factors driving the stock performance of Ind-Swift Laboratories Ltd and Kobo Biotech Ltd?

The stock performance of Ind-Swift Laboratories Ltd and Kobo Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ind-Swift Laboratories Ltd and Kobo Biotech Ltd?

As of July 8, 2025, the Ind-Swift Laboratories Ltd stock price is INR ₹119.8. On the other hand, Kobo Biotech Ltd stock price is INR ₹2.4.

How do dividend payouts of Ind-Swift Laboratories Ltd and Kobo Biotech Ltd compare?

To compare the dividend payouts of Ind-Swift Laboratories Ltd and Kobo Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions